IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer

Kirner, Alexandra; Mayer-Mokler, Andrea; Reinhardt, Carsten

doi:10.4161/21645515.2014.983857

Cited by 48 publications

(31 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant differences in any AE with a frequency of greater than 5% were seen between the groups. IMA901‐specific CD8‐positive T‐cell responses were reduced threefold in magnitude compared with data from phase I‐II trials of the same vaccine in metastatic RCC and other solid tumors . Moreover, by contrast with the previous phase II metastatic RCC trial, we did not find a clear association of T‐cell responses with clinical outcome.…”

Section: Combination Therapy Using Peptide‐based Vaccinecontrasting

confidence: 90%

Present status and future perspective of peptide‐based vaccine therapy for urological cancer

et al. 2018

View full text Add to dashboard Cite

Use of peptide‐based vaccines as therapeutics aims to elicit immune responses through antigenic epitopes derived from tumor antigens. Peptide‐based vaccines are easily synthesized and lack significant side‐effects when given in vivo. Peptide‐based vaccine therapy against several cancers including urological cancers has made progress for several decades, but there is no worldwide approved peptide vaccine. Peptide vaccines were also shown to induce a high frequency of immune response in patients accompanied by clinical efficacy. These data are discussed in light of the recent progression of immunotherapy caused by the addition of immune checkpoint inhibitors thus providing a general picture of the potential therapeutic efficacy of peptide‐based vaccines and their combination with other biological agents. In this review, we discuss the mechanism of the antitumor effect of peptide‐based vaccine therapy, development of our peptide vaccine, recent clinical trials using peptide vaccines for urological cancers, and perspectives of peptide‐based vaccine therapy.

show abstract

Section: Combination Therapy Using Peptide‐based Vaccinecontrasting

confidence: 90%

Present status and future perspective of peptide‐based vaccine therapy for urological cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Actually, few papers have described surveys of tumor-associated immunopeptidomes with identifications of more than 100 HLA-bound peptides [60, 66, 67]. For example, Bassani-Sternberg et al [60] developed a high-throughput MS-based workflow that yielded more than 22,000 unique HLA peptides across seven cancer cell lines and primary cells.…”

Section: Discussionmentioning

confidence: 99%

MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection

Rozanov

Chiotti

et al. 2018

Journal of Proteomics

View full text Add to dashboard Cite

Breast cancer therapy based on amplifying a patient’s antitumor immune response depends on the availability of appropriate MHC class I-restricted, breast cancer-specific epitopes. To build a catalog of peptides presented by breast cancer cells, we undertook systematic MHC class I immunoprecipitation followed by elution of MHC class I-loaded peptides in breast cancer cell lines. We determined the sequence of 3,196 MHC class I-bound peptides representing 1,921 proteins from a panel of 20 breast cancer cell lines including basal, luminal, and claudin-low subtypes. The data has been deposited to the ProteomeXchange with identifier PXD006406. After removing duplicate peptides, i.e., the same peptide eluted from more than one cell line, the total number of unique peptides was 2,740. Of the unique peptides eluted, more than 1,750 had been previously identified, and of these, sixteen have been shown to be immunogenic. Importantly, only 3 of these immunogenic peptides have been identified in breast cancer cells in earlier studies. MHC class I binding probability of eluted peptides was used to plot the distribution of MHC class I allele-specific peptides in accordance with the binding score for each breast cancer cell line. We also determined that the tested breast cancer cells presented 89 mutation-containing peptides and peptides derived from aberrantly translated genes, 7 of which were shared between four or two different cell lines. Overall, the high throughput identification of MHC class I-loaded peptides is an effective strategy for systematic characterization of cancer peptides, and could be employed for design of multi-peptide anticancer vaccines.

show abstract

“…Similarly, the use of checkpoint inhibitors in combination with vaccines would make for an interesting next-generation approach in treating ccmRCC, given their potentially complementary stimulation of the adaptive immune response. Such combinations have already been considered for off-the-shelf vaccines like IMA901, for example [65,66]. Additionally, combinations of the checkpoint inhibitor ipilimumab with autologous vaccines are currently being evaluated clinically [67,68].…”

Section: Expert Opinionmentioning

confidence: 99%

Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma

Figlin¹

2015

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer

Cited by 48 publications

References 82 publications

Present status and future perspective of peptide‐based vaccine therapy for urological cancer

Present status and future perspective of peptide‐based vaccine therapy for urological cancer

MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection

Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma

Contact Info

Product

Resources

About